ALAMEDA, Calif.--(BUSINESS WIRE)--Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Fran Soistman has joined the company’s Scientific Advisory Board (SAB). Soistman is an accomplished business executive who has decades of experience driving profitable growth for healthcare entities. As a member of Alveo’s SAB Soistman will leverage his proven track record leading and governing healthcare businesses to provide strategic support in Alveo’s efforts to bring to market the company’s be.well™ platform, a point-of-care and at-home diagnostic tool currently under development.
“Fran has a longstanding history of successfully leading healthcare companies of all sizes – from startups to well-established entities – and driving results,” said Ron Chiarello, PhD, Chairman, CEO and Founder of Alveo. “With the current global need for rapid and reliable infectious disease diagnostics, our mission to make these capabilities available in the home and to help individuals connect to the right kind of care is critical. Fran’s expertise in the business of healthcare will provide Alveo with the necessary insights to put the be.well™ platform in the hands of clinicians as quickly as possible to contain infectious diseases and avoid future public health crises.”
Soistman brings to Alveo’s SAB more than 40 years of diverse experience in healthcare and managed care. In his most recent role, Soistman served as the Executive Vice President for Aetna, a CVS Health Company, where his core focus was to drive profitable growth for the company. Throughout his career, Soistman has held several executive leadership positions and has pioneered new innovations, from products to funding arrangements – like the first pre-funded health insurance program for retirees. He has also led several business turnarounds and has had great success in accelerating sustainable business growth. As a member of the SAB, Soistman will leverage his deep industry knowledge to guide Alveo’s efforts in driving growth for, and implementation of, affordable and convenient testing of infectious diseases in the consumer market in order to enable faster, more precise interventions.
“I am greatly looking forward to impacting Alveo’s progress with its be.well™ platform, and supporting its goal of bringing rapid, wide-spread diagnostics to the masses,” said Soistman. “The work Alveo has done to bring to life an affordable, user-friendly, at-home diagnostic platform is incredibly forward-thinking and has the potential to completely alter the way healthcare leaders and public health officials navigate disease detection and management. It is exciting to be part of such an innovative group and to have a hand in influencing the expansion of the be.well™ platform.”
To learn more about Alveo’s Scientific Advisory Board, visit: https://alveotechnologies.com/about/.
Alveo is leading the transformation of the consumer health tech market with a low-cost, easy-to-use, at-home diagnostic platform that will change the way infectious diseases are detected and managed. The company’s be.well™ testing system gives individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections, including COVID-19, Influenza A/B and RSV, Alveo’s agile and dynamic diagnostic platform can be adapted to detect a wide range of diseases that threaten public health. Affordable access to real-time, at-home results will transform the way individuals, healthcare providers and public health professionals identify and manage disease outbreaks. With be.well™, we will know sooner, act faster and make better-informed decisions toward personalized intervention options that benefit individuals and the entire population. To learn more, visit https://alveotechnologies.com/.